Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Depreciation & Amortization (CF) (2023 - 2025)

Mangoceuticals (MGRX) has disclosed Depreciation & Amortization (CF) for 3 consecutive years, with $255.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) changed 0.0% to $255.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1013.0 through Dec 2025, down 89.8% year-over-year, with the annual reading at $1012.0 for FY2025, 89.81% down from the prior year.
  • Depreciation & Amortization (CF) hit $255.0 in Q4 2025 for Mangoceuticals, roughly flat from $256.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $12515.0 in Q3 2023 to a low of $250.0 in Q1 2025.
  • Historically, Depreciation & Amortization (CF) has averaged $3823.8 across 3 years, with a median of $3457.0 in 2024.
  • Biggest five-year swings in Depreciation & Amortization (CF): grew 2.33% in 2024 and later crashed 95.98% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $6292.0 in 2023, then crashed by 95.95% to $255.0 in 2024, then changed by 0.0% to $255.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for MGRX at $255.0 in Q4 2025, $256.0 in Q3 2025, and $252.0 in Q2 2025.